People

Dr. Sandra Burgstaller
Scientist Recombinant Antibody Technology
Desiree Frecot
Scientist Recombinant Antibody Technologies
Ursula Härle
Technical Assistant Recombinant Antibody Technologies
Dr. Philipp Kaiser
Scientist Recombinant Antibody Technologies
Prof. Dr. Ulrich Rothbauer
Groupleader Recombinant Antibody Technology

Stages of career

01/2018 - 12/2021 Head of Department PharmaBiotech at with the Natural and Medical Sciences Institute at the University of Tuebingen, NMI)
 
Since 11/2011 Professor for Pharmaceutical Biotechnology at the University of Tuebingen
(Joint Professorship with the Natural and Medical Sciences Institute at the University of Tuebingen, NMI)
 
2008 – 2011                 
CEO of the Biotech company ChromoTek GmbH (Martinsried)
 
2008 – 2010 Junior Group leader, GO-Bio, Biocenter, LMU
 
2006 – 2007 Project leader „Chromobodies“ Exist Seed Group, Biocenter, LMU
 
2004 – 2005 Postdoctoral Fellow in the lab of Prof. Dr Heinrich Leonhardt, Biocenter, LMU,
 
2003 – 2004 Postdoctoral Fellow in the lab of PD Dr. Mathias Bauer, Institute of Diabetic Research Academic Hospital, Munich
 

 

 

Dr. Björn Tränkle
Scientist Recombinant Antibody Technologies

Areas of activity

Preclinical development of biologics, Discovery, production, functionalization and cellular testing of remobinant binding molecules (anitbodies, anitbody-derivatives, nanobodies) for diagnostics molecular imaging (PET imaging) and therapeutic immunomodulation

Stages of career

2020 - present  Scientist at Recombinant Antibody Technologies Group with Prof. Dr. Ulrich Rothbauer

2013 - 2020  Postdoc at University of Tuebingen, Pharmaceutical Biotechnology Group with Prof. Dr. Ulrich Rothbauer

2010 -2013  Dissertation (Dr. rer. nat.; PhD) at NMI / Universtiy of Tuebingen with Prof. Dr. Michael Schwarz and Prof. Dr. Stefan Laufer: "The Role of PLexin A4 in the regulation of proliferation and apoptosis of Prostate Cancer Cells".

2009  Diploma Thesis in Biochemistry at NMI, Molecular Biology Groupd with Frank Weise: "Suitability analysis of the proteins G2E3, CCAR1, GREB1 and Nur77 as biomarker or therapeutic target for oncotherapy"

2002 - 2009  Study of Biochemistry at the Eberhard Karls University in Tuebingen and Montana State University in Bozeman, USA (2005 - 2006)

Teresa Wagner
Scientist Recombinant Antibody Technologies

Student Assistants

Aiden Tamaddon
Studentische Mitarbeiter Rekombinante Antikörpertechnologien